• Apr6

    CGI Adopts the Avoca Diligent Prequalification Platform to Help Sponsors in the Clinical Trial Vendor Selection Process

    Written by: Anna Israyelyan, MD, PhD , Manager, Clinical Affairs

    Anna Israyelyan, MD, PhD

    As an oncology diagnostic and clinical trial service provider, CGI recently became an early adopter of the innovative Avoca Diligent Prequalification Platform by The Avoca Group. THE ADDED VALUE OF AVOCA DILIGENT PREQUALIFICATION PLATFORM Increase quality, Improve efficiency, Reduce risk, and Accelerate the selection of critical clinical trial service providers Recently, the Avoca Group invited […]

    » Continue Reading

  • Mar20

    CGI’s Response to the Genomics Gap in Renal Cancer Drug Development

    Written by: Anna Israyelyan, MD, PhD , Manager, Clinical Affairs

    Anna Israyelyan, MD, PhD

    Focus::Renal™ – The Most Comprehensive Molecular Profiling Tool for Kidney Cancer Clinical Testing & Clinical Trial Testing The presentation, “Genomics of RCC” at the 3rd Annual Summit on Genitourinary Malignancies in NYC in October 2016 was by an internationally recognized leader in the area of genitourinary cancers Sumanta (Monty) Kumar Pal, MD.  Dr. Pal presented […]

    » Continue Reading

  • Mar2

    CGI’s Comprehensive Approach to Liquid Biopsy

    Written by: Anna Israyelyan, MD, PhD , Manager, Clinical Affairs

    Anna Israyelyan, MD, PhD

    TECHNOLOGY AGNOSTIC LIQUID BIOPSY SOLUTIONS As liquid biopsies have become an area of intense research, commercial activity, and a reality in cancer treatment, Cancer Genetics, Inc. (CGI; Nasdaq: CGIX) has actively taken steps to continue at the forefront in cancer diagnostics by evaluating and qualifying liquid biopsy tests for a broad range of indications. Liquid […]

    » Continue Reading

  • Feb17

    Going to Tri-Con Next Week?

    Written by: Anna Israyelyan, MD, PhD , Manager, Clinical Affairs

    Anna Israyelyan, MD, PhD

    If you are part of the diagnostics and drug discovery ecosystem, the Tri-Conference ranks as one of the must attend events of the year. The week-long event is scheduled to kick off this Sunday, February 19th, in beautiful San Francisco. With a 24 year history of delivering molecular medicine and diagnostics breakthroughs and technologies, the […]

    » Continue Reading

  • Feb8

    Insight into CGI’s Molecular Diagnostics Work in India

    Written by: Anna Israyelyan, MD, PhD , Manager, Clinical Affairs

    Anna Israyelyan, MD, PhD

    Based in Hyderabad, CG India (previously BioServe India, now a CGI Company) offers Indian scientists, pharmaceutical companies, and research institutes a full suite of molecular services and research tools to accelerate breakthroughs in genetics, drug discovery, biomarker research, and molecular diagnostics. CG India’s customers include nearly every Indian Council of Medical Research (ICMR) and Council […]

    » Continue Reading

  • Feb2

    Will You Be in San Diego February 6th and 7th? Be Our Guest at the 2nd Annual Biomarker Conference

    Written by: Anna Israyelyan, MD, PhD , Manager, Clinical Affairs

    Anna Israyelyan, MD, PhD

    Due to the overwhelming response to the first ever Biomarker Conference last year, scheduled attendance for the 2nd Annual Biomarker Conference is shaping up to surpass last year’s success. As you might suspect, the agenda is shaped around the “hot” topics in Precision Medicine: companion diagnostics (CDx), immuno-oncology (IO), and next generation sequencing (NGS). As […]

    » Continue Reading

  • Jan25

    Key Takeaways from ASH 2016: Novel Genomic Evaluation of Aggressive Lymphomas

    Written by: Anna Israyelyan, MD, PhD , Manager, Clinical Affairs

    Anna Israyelyan, MD, PhD

    The most compelling things we learned at the American Society of Hematology (ASH) 2016 annual meeting last month were the many advances in the novel molecular characterization, evaluation, and applications for aggressive lymphomas. At a standing room only session dedicated to diffuse large B-cell lymphoma (DLBCL), various studies outlined the new possibilities in prognosis, treatment, […]

    » Continue Reading

  • Nov29

    Meet with Cancer Genetics at ASH

    Written by: Anna Israyelyan, MD, PhD , Manager, Clinical Affairs

    Anna Israyelyan, MD, PhD

    At the world’s premier event in hematology, the American Society of Hematology (ASH) Annual Meeting will provide it’s over 20,000 attendees with an opportunity to explore the year’s most significant research and discoveries in the field.  It’s also a time to connect with old friends, meet new ones, and learn about the latest industry trends. […]

    » Continue Reading

  • Nov8

    “Big World. Molecular Medicine. One Community” – Cancer Genetics’ Contributions to AMP this Year

    Written by: Anna Israyelyan, MD, PhD , Manager, Clinical Affairs

    Anna Israyelyan, MD, PhD

    Every year, the Association for Molecular Pathology (AMP) hosts a 3-day event, which provides high quality content  for the global molecular pathology community. As a leader in enabling precision medicine for oncology through molecular markers and diagnostics,  Cancer Genetics, Inc. (CGI) will contribute to the meeting’s theme through its carefully selected presentations and important insights. […]

    » Continue Reading

  • Sep19

    The Value of Precision Medicine Quantified

    Written by: Jared Jacobson MBA, MMB, Market Development Associate

    Jared Jacobson

    In late 2013, the FDA published Paving the Way for Personalized Medicine: FDA’s Role in a New Era of Medical Product Development, with the intention of describing the agency’s goals to help drive personalized treatments and diagnostics. Within the introduction it is stated that “elegant science” and “well-designed” personalized medicine programs have created the opportunity […]

    » Continue Reading

  • Aug17

    Who Owns Personalized Medicine? Answer: Pathologists for now…

    Written by: Jared Jacobson MBA, MMB, Market Development Associate

    Jared Jacobson

    Pathologists are occupying an ever more critical station in the continuum of care between patients and oncologists as innovation in both diagnostics and therapies continue to advance at an accelerating rate. The AML patient who would have been placed directly on chemotherapy just a few years ago, now may be identified for bone marrow transplant […]

    » Continue Reading

  • Jul27

    The Questions We Always Face in Every One of Our Clinical Trial Discussions…

    Written by: Jared Jacobson MBA, MMB, Market Development Associate

    Jared Jacobson

    How often has the testing strategy in your clinical trial been limited by sample availability? What possible biomarker targets have you had to eliminate due to budget constraints? How do you parse the data you generate and develop actionable results? Providing solutions to these pragmatic and critical issues drove CGI’s decision to validate the Focus::Oncomine™ […]

    » Continue Reading

  • Jul12

    Successful Clinical Trials Hinge on Sample Integrity. Who’s Taking Care of Yours?

    Written by: Jared Jacobson MBA, MMB, Market Development Associate

    Jared Jacobson

    Biological specimen management is one of the most critical components of clinical trial design and is embodied by a complex network of handling, processing, and testing. Every point of contact represents a new chance for errors or corruption to be introduced to the extremely valuable, finite sample material.

    » Continue Reading

  • Jul5

    Does Your Immunooncology Program Need Dako 22C3 or Ventana SP263? CGI Runs All Four PD-L1 IHC Clones. Let’s Find Out Which Works Best For You.

    Written by: Jared Jacobson MBA, MMB, Market Development Associate

    Jared Jacobson

    PD-L and PD-L1 inhibitors will continue leading the paradigm shift in oncology toward immunotherapy for the foreseeable future. The PD-L1 IHC assays that have been developed as therapeutically paired diagnostics are now being pressed into service for hundreds of new combination treatments and indication expansions. Currently, four unique clones have reached clinical practice across Agilent’s […]

    » Continue Reading

  • Jun14

    CGI Brings the Powerful, Flexible Chemistry of ArcherDX NGS to Clinical Trials

    Written by: Jared Jacobson MBA, MMB, Market Development Associate

    Jared Jacobson

    Clinically relevant biomarkers are being identified at an accelerating rate, placing an ever greater premium on the importance of limited patient tissue samples. This in turn increases the already daunting complexity of clinical trial design and leads to questions that strike at the heart of successful drug development. With a finite capacity to run diagnostic […]

    » Continue Reading

  • Apr25

    Flow Cytometry is Now an Integral Component of Comprehensive Immuno-oncology Biomarker Strategy

    Written by: Jared Jacobson MBA, MMB, Market Development Associate

    Jared Jacobson

    Flow cytometry has long been a mainstay of the diagnostic regime for hematological cancers. Now with the rise of immunotherapies, CGI is at the innovative front establishing a new place for this technology in both hematological and solid tumor cancers.

    » Continue Reading

  • Apr12

    Are You Testing for DTX1 in Your Lymphoma Trial? What About FAT2 or FAT4? The CGI Team has Designed Focus::Lymphoma NGS to Interrogate the Genes You Need.

    Written by: Jared Jacobson MBA, MMB, Market Development Associate

    Jared Jacobson

    Our Lymphoma panel is already being integrated into several industry-leading B-cell malignancy trials. Whether you are interested in retrospectively profiling previous clinical trial cohorts – or incorporating these data into an exploratory endpoint of an upcoming trial, we have designed Focus::Lymphoma with reproducibility and therapeutic impact foremost in mind.

    » Continue Reading